Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2020

View Archived Issues

IRDye800CW-nimotuzumab enters phase I/II study for image-guided lung cancer surgery

Q32 Bio begins phase I study with ADX-914 in healthy volunteers

Regeneron initiates phase I study of NPR1 agonist REGN-5381

Prion protein's positive point

"Fight or flight" nervous system helps fight tumors, too

Preliminary results support ongoing development of Biogen's BTK inhibitor

Dosing starts in phase I study of exoIL-12

EMA approves label update for HyQvia

Arbutus presents continued positive data from first-in-human study of AB-729

SAB-402, a novel potent dual EGFR/HER4 tyrosine kinase inhibitor with promising activity in vivo

Specific PAC1 receptor antibody as potential new treatment of primary headaches

RNA-targeted CRISPR reverses myotonic dystrophy symptoms

Bioardis divulges new FGFR4 inhibitors

C4 Therapeutics patents new CRBN-targeting compounds

Bristol-Myers Squibb identifies TYK2 inhibitors

FDA clears IND for bispecific antibody EMB-02 for solid tumors

AC Immune identifies new MAPT aggregation inhibitors

Sec61 protein secretion-interfering compounds presented by Kezar Life Sciences

New animal model created to study cerebellar dysfunction in multiple sclerosis

Phase III trial of ganaxolone in CDKL5 deficiency disorder meets primary endpoint

AQP4 and Cx43 expression alteration leads to neuromyelitis optica

Escient initiates phase I/Ib study of EP-547 to treat cholestatic and uremic pruritus

New preclinical data reported on ICON-2 for solid tumors

Grant supports Melior's evaluation of tolimidone for COVID-19

Innovation Pharmaceuticals reports new in vitro data on use of brilacidin for COVID-19

Lilly reports interim phase II data on SARS-CoV-2 neutralizing antibody LY-CoV555

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....